Leerink Partnrs Issues Negative Estimate for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities research analysts at Leerink Partnrs dropped their Q1 2025 EPS estimates for shares of Zentalis Pharmaceuticals in a report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of ($0.69) per share for the quarter, down from their prior forecast of ($0.68). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ FY2025 earnings at ($2.01) EPS and FY2026 earnings at ($1.82) EPS.

A number of other research analysts have also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 27th. UBS Group decreased their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Wells Fargo & Company dropped their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Finally, Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, March 28th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Zentalis Pharmaceuticals has a consensus rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL opened at $1.39 on Monday. The firm has a market cap of $99.82 million, a P/E ratio of -0.56 and a beta of 1.75. Zentalis Pharmaceuticals has a 1 year low of $1.36 and a 1 year high of $16.21. The stock has a 50 day simple moving average of $2.01 and a two-hundred day simple moving average of $2.83.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million for the quarter.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, Director Jan Skvarka purchased 60,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the purchase, the director now directly owns 149,551 shares in the company, valued at $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingmar Bruns acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The shares were acquired at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the purchase, the insider now directly owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ZNTL. Barclays PLC raised its stake in Zentalis Pharmaceuticals by 18.5% during the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after buying an additional 11,748 shares during the last quarter. Verition Fund Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after acquiring an additional 951,500 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Zentalis Pharmaceuticals by 115.6% in the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock worth $171,000 after purchasing an additional 30,240 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Zentalis Pharmaceuticals by 22.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock worth $1,507,000 after purchasing an additional 91,152 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at about $76,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.